Cancer Drug Design and Discovery

by Stephen Neidle (Editor)

Overview

The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry and clinicians taking oncology options.

* Covers both currently available drugs as well as those under development
* Provides a clinical perspective on trials of new anticancer agents
* Presents drug discovery examples through the use of case histories

Product Details

ISBN-13:	9780080554952
Publisher:	Elsevier Science
Publication date:	04/28/2011
Sold by:	Barnes & Noble
Format:	eBook
Pages:	496
File size:	16 MB
Note:	This product may take a few minutes to download.

About the Author

Stephen Neidle is an Emeritus Professor of Chemical Biology at University College London, where he has also been the Director of Research in the School of Pharmacy. He has published over 500 primary papers and reviews and is a principal inventor on 14 patent filings. He has also written and edited several books on nucleic acids and anti-cancer drugs.

Table of Contents

Section I. Basic Principles
1. Modern cancer drug discovery: Integrating targets, technologies and treatments
2. Preclinical pharmacology and in vivo models
3. Clinical trial designs for more rapid proof-of-principle and approval

Section II. Methodology
4. Structural biology and anticancer drug design
5. Natural product chemistry and cancer drug discovery
6. Pharmacokinetics&ADME optimization in drug discovery

Section III. Drugs in the clinic and laboratory
7. Temozolomide: from cytotoxic to molecularly-targeted agent
8. Camptothecins for drug design, cancer cell death and gene targeting
9. Targeting thymidylate synthase by antifolate drugs for the treatment of cancer


Section IV. New Agents
10. Targeting inactive kinases: structure as a foundation for cancer drug discovery
11. Cell cycle inhibitors in cancer: current status and future directions
12. Inhibition of DNA repair as a therapeutic target
13. Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways
14. Heat shock protein-90-directed therapeutics and target validation
15. Inhibitors of tumour angiogenesis
16. The biology and oncology of RAF–ERK signalling P53 as a therapeutic target


Section V. The reality of cancer drugs in the clinic
17. Cancer drug resistance
18. Failure Modes in Anticancer Drug Discovery and Development

What People are Saying About This

From the Publisher

The second edition of this authoritative reference features the latest on the design and development of new anticancer small molecules, including topics such as the identification of molecular targets, cancer genomics, personalized medicine and more.

Editorial Reviews

"…offers unique information on the discovery and design of new anticancer agents, covering recent notable successes resulting from the human genome and cancer genomics projects…an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry…" —Anticancer Research 34, 2014

"The second edition of this book walks readers through the myriad cancer drugs and their molecular targets, with a special emphasis on past, present, and future drug design efforts... the book examines both drugs currently in the clinic and those merely on the drawing board…This comprehensive update of the 2008 edition will serve student or experienced cancer researchers well as a reference on anticancer drug development." Rating: 4 Stars —Doody.com, March 21, 2014

"Specialists in cancer and pharmaceuticals, most in academic settings, look at basic principles of cancer drugs, methodology, drugs in the clinic, new agents, and the reality of cancer drugs in the clinic…They do include many case studies, and some chapters provide questions for classroom use." —ProtoView.com, February 2014

From the Publisher

Reviewer: Jed N. Lampe, Ph.D.(University of Kansas Medical Center)
Description: Of all the diseases amenable to therapeutic intervention, cancer has proven to be the most intractable. This is at least in part due to the fact that cancers can have multiple molecular etiologies and mechanisms. The second edition of this book walks readers through the myriad cancer drugs and their molecular targets, with a special emphasis on past, present, and future drug design efforts. After a comprehensive introduction, each chapter focuses on a different set of drugs and therapeutic targets, allowing readers to explore in detail a particular cancer target they are interested in.
Purpose: The goal of this edition, like the first, is to go through the entire process of cancer drug discovery and development — from target elucidation, to lead discovery and optimization, to clinical trial evaluation. These are worthwhile goals and the book examines both drugs currently in the clinic and those merely on the drawing board. Additionally, it also serves a second function as a textbook, with very comprehensive, yet readable, introductory chapters on the basic principles of cancer drug discovery and development.
Audience: Although the primary audience is cancer research scientists and clinicians, students interested in a behind-the-scenes look at cancer drug discovery also will find it immensely useful. The editor is a distinguished cancer chemical biology researcher at the School of Pharmacy, University College, London, and the book profits from his many decades of experience in the field.
Features: Professor Neidle has gathered a variety of professionals from industry, academia, and government to tell their individual tales of the discovery and development of various anticancer agents. Introductory chapters provide an overview of many agents derived from natural products, while the rest of the book is dedicated to drugs that are either currently prescribed in the clinic or are in various stages of clinical development. Of particular note are some of the more recently developed therapeutic agents, such as abiraterone (for prostate cancer), or antiangiogenesis agents. There are numerous illustrations and through bibliographies in each chapter. It's unfortunate that the illustrations are not in full color, but they are they are clear and crisp and reinforce the important concepts in the chapter.
Assessment: This comprehensive update of the 2008 edition will serve student or experienced cancer researchers well as a reference on anticancer drug development.

Doody's Review Service